VATS or Intrapleural Enzymatic Therapy for patientS with empyema (the VIETS trial)

Condition studied

Parapneumonic pleural infection/pleural empyema

Investigational medicinal product(s)

Eligibility

Primary endpoint

Length of hospital stay (LOS) during the first 30 days.

Endpoint detail

Measures related to treatment (duration of chest tube drainage, delayed discharge days, re-intervention and re-admission rates, morbidity, mortality, type and duration of antibiotic treatment and pain medication)., Patient reported outcomes (pain, health related quality of life, limitations in daily activities, return to work)., Economic evaluation (healthcare costs, costs of patient, costs of productivity loss, health related quality of life).